Completed

APPEAL-TaiwanA Study of Bimatoprost 0.01% in the Clinical Setting

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being collected

Drug Data

+ drug Data

Collected from today forward - Prospective
Drug
Who is being recruted

Eye Diseases+1

+ Glaucoma

+ Glaucoma, Open-Angle

Over 20 Years
+3 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Case-Only

Examining characteristics of individuals with a disease in order to identify genetic or environmental factors contributing to the condition.
Observational
Study Start: May 2013
See protocol details

Summary

Principal SponsorAllergan
Last updated: October 26, 2015
Sourced from a government-validated database.Claim as a partner

Study start date: May 1, 2013

Actual date on which the first participant was enrolled.

This is a study of bimatoprost 0.01% (LUMIGAN® 0.01%) in subjects with primary open-angle glaucoma (POAG) or ocular hypertension (OH) who require further treatment for elevated intraocular pressure (IOP).

NCT01814761
Principal SponsorAllergan
Last updated: October 26, 2015
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

312 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Case-only

These studies focus only on individuals who have a specific disease. Researchers examine patterns—often genetic or environmental—to uncover what might be linked to the condition.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 20 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Eye DiseasesGlaucomaGlaucoma, Open-AngleOcular Hypertension

Criteria

2 inclusion criteria required to participate
Determined by the treating physician to require treatment with bimatoprost 0.01%
Diagnosis of primary open-angle glaucoma or ocular hypertension
1 exclusion criteria prevent from participating
Previous use of Lumigan 0.01%

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

2 intervention groups are designated in this study

This study does not include a placebo group 

Treatment Groups

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Taichung, TaiwanOpen in Google Maps
CompletedOne Study Center